DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION<sup>1</sup>

Liuzzi, Antonio; Chiodini, P. G.; Botalla, L; Cremascoli, G.; Müller, Eugenio E.; Silvestrini, F

doi:10.1210/jcem-38-5-910

Cited by 204 publications

(65 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration of dopaminergic agonists to normal men results in an elevation of the circulating levels of GH (1)(2)(3)(4). In contrast, the same maneuver has been shown to decrease serum GH levels in most, though not all, patients with acromegaly (3,(5)(6)(7)(8). On the basis ofthis finding, bromocriptine, a dopaminergic agonist with a prolonged action, has been successfully introduced into the medical management of this disorder (9)(10)(11)(12).…”

mentioning

confidence: 99%

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Ishibashi¹,

Yamaji²

1984

J. Clin. Invest.

View full text Add to dashboard Cite

A bstract. To determine the mechanism and the site of action of catecholamines as well as hormones including thyrotropin-releasing hormone (TRH)' and somatostatin on pituitary hormone release in patients with acromegaly and in normal subjects, the effects of these substances on growth hormone (GH) and prolactin (PRL) secretion from adenomatous and nonadenomatous human pituitary cells in culture were examined. When dopamine (0.01-0.1 tM) or bromocriptine (0.01-0.1 tM) was added to the culture media, a significant inhibition of GH

show abstract

mentioning

confidence: 99%

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Ishibashi¹,

Yamaji²

1984

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…GH levels are elevated by TRH and LHRH, in 70-80% and 30%, respectively, of acromegalic patients (Irie and Tsushima 1972;Hanew et al 1980;Utsumi et al 1992). Dopamine agonists stimulate GH secre-tion in normal individuals, but paradoxically inhibit it in 59-70% of acromegalic patients (Liuzzi et al 1974). However, in the two cases of our patients, GH levels were increased in response to bromocriptine.…”

Section: Discussionmentioning

confidence: 44%

Usefulness of the Thyrotropin-Releasing Hormone Test in Pre-Clinical Acromegaly

Kageyama

Moriyama

Sakihara

et al. 2005

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Acromegaly is caused primarily by pituitary growth hormone (GH)-secreting tumors. It is usually recognized because of characteristic manifestations, and diagnosed clinically. However, there exists a mild stage of acromegaly, which poses a diagnostic problem due to the absence of typical clinical manifestations. Here we present four patients with pre-clinical acromegaly, who showed minimal acromegaloid features with elevated levels of insulin-like growth factor-I. Basal GH levels were within normal levels in 3 of 4 cases, while insulin-like growth factor-I levels were elevated above normal in all cases. Plasma GH levels were elevated in response to thyrotropin-releasing hormone (TRH) in all cases, indicating a diagnostic value of the TRH stimulation test. In contrast, an oral glucose tolerance test was not useful for the diagnosis, because of the low GH levels (less than 1 ng/ml) and/or secondary to diabetes mellitus. In response to a dopamine agonist, GH levels were increased in the two cases, whereas GH levels were decreased or remained unchanged in the other two cases. We therefore suggest that the TRH stimulation test would be helpful to examine the presence of pre-clinical acromegaly. Diagnosis of the early stages of acromegaly is important to prevent progression to overt acromegaly. growth hormone; acromegaly; insulinlike growth factor-I; pituitary tumor

show abstract

“…Actually, the decrease of plasma GH level after a single oral dose of CB-154 was reported in acromegalic patients (Liuzzi et al, 1974) during the .preparing of the present paper. This mechanism is unclear, but it might be speculated from the data of analogous experimental pituitary tumors that seme cells of the present tumor were able to produce both prolactin and GH and under the inhibitory influences by CB-154 treatment…”

Section: Discussionmentioning

confidence: 53%

Effects of CB-154 (2-Br-α-Ergocryptine) on Prolactin and Growth Hormone Release in an Acromegalic Patient with Galactorrhea

et al. 1975

View full text Add to dashboard Cite

DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION¹

Cited by 204 publications

References 0 publications

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Usefulness of the Thyrotropin-Releasing Hormone Test in Pre-Clinical Acromegaly

Effects of CB-154 (2-Br-α-Ergocryptine) on Prolactin and Growth Hormone Release in an Acromegalic Patient with Galactorrhea

Contact Info

Product

Resources

About

DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION1

Cited by 204 publications

References 0 publications

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.

Usefulness of the Thyrotropin-Releasing Hormone Test in Pre-Clinical Acromegaly

Effects of CB-154 (2-Br-α-Ergocryptine) on Prolactin and Growth Hormone Release in an Acromegalic Patient with Galactorrhea

Contact Info

Product

Resources

About

DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION¹